Ontology highlight
ABSTRACT:
SUBMITTER: Vichinsky E
PROVIDER: S-EPMC3170481 | biostudies-literature | 2011 Aug
REPOSITORIES: biostudies-literature
Vichinsky Elliott E Bernaudin Françoise F Forni Gian Luca GL Gardner Renee R Hassell Kathryn K Heeney Matthew M MM Inusa Baba B Kutlar Abdullah A Lane Peter P Mathias Liesl L Porter John J Tebbi Cameron C Wilson Felicia F Griffel Louis L Deng Wei W Giannone Vanessa V Coates Thomas T
British journal of haematology 20110519 3
To date, there is a lack of long-term safety and efficacy data for iron chelation therapy in transfusion-dependent patients with sickle cell disease (SCD). To evaluate the long-term safety and efficacy of deferasirox (a once-daily oral iron chelator), patients with SCD completing a 1-year, Phase II, randomized, deferoxamine (DFO)-controlled study entered a 4-year extension, continuing to receive deferasirox, or switching from DFO to deferasirox. Average actual deferasirox dose was 19·4 ± 6·3 mg/ ...[more]